Fusome

Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform and Advancements with its In Vivo Fusogen Platform with Four Presentations at the 2023 AACR Annual Meeting

Retrieved on: 
Wednesday, April 19, 2023
AACR, Biotechnology, Fusome, CD19, IL-7, Cell, Hematological Cancer Research Investment and Education Act, CAR, HIP, Animal, Patient, Immune system, Poster, Neoplasm, SANA, Sana, Therapy, IND, Vaccine, Pharmaceutical industry

“At AACR, we presented data highlighting the potential of our hypoimmune platform to “hide” allogeneic CAR T cells from immune recognition, improving CAR T cell persistence and anti-tumor effect.

Key Points: 
  • “At AACR, we presented data highlighting the potential of our hypoimmune platform to “hide” allogeneic CAR T cells from immune recognition, improving CAR T cell persistence and anti-tumor effect.
  • Other data highlighted the progress and potential of SG299, the first drug candidate from our fusogen platform, in generating CD19-directed CAR T cells with in vivo delivery.
  • The study results showed that HIP CD19-directed CAR T cells were functionally immune evasive in allogeneic humanized mouse models.
  • When given systemically, IL-7 supported the expansion of in vivo fusosome-generated CAR T cells and increased anti-tumor efficacy compared to fusosome only.

Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Retrieved on: 
Thursday, March 16, 2023
Gene editing, BCMA, Research and development, IND World's Fair Line, Stem cell, Development, Culture, Cancer, Bangladesh Technical Education Board, CD47, Epithelium, ADA, Hepatocyte, State Administrative Expenses, CAR, ISSCR, CD19, Cell, Success, Immune system, Diabetes, Research, CD22, AACR, Lymphoid leukemia, NIH, Patient, ASH, Safety, Letter, Contingency, Retinal pigment epithelium, Serum, Survival, SANA, Autoimmunity, Administration, Immunosuppression, Fusome, Investment, GAAP, Disease, Biotechnology, IND, Mobile phone, Pharmaceutical industry, Vaccine, Cryptocurrency, Beam

SEATTLE, March 16, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • SEATTLE, March 16, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2022.
  • Sana expects an investigator sponsor trial using primary human hypoimmune-modified islet cells transplanted in type 1 diabetes patients to begin later this year.
  • In 2022, Sana transitioned to a new manufacturing process for SG295 and renamed the product SG299 in connection with that transition.
  • A discussion of non-GAAP measures, including a reconciliation of GAAP and non-GAAP measures, is presented below under “Non-GAAP Financial Measures.”

ShiftBio Partners with RoosterBio to Accelerate Development of a Novel Genetically Engineered Exosome, SBI-102 for Rare Diseases and Cancer

Retrieved on: 
Tuesday, April 26, 2022
Microsoft, CEO, Genetic engineering, Exosome, IND, Degenerative disease, Entrepreneurship, Program, Patient, II, Technology, CGMP, Safety, FDA, Partnership, Cancer, Bioreactor, Therapy, MSC, Fine chemical, 3D printing, Pharmaceutical industry, Fusome

FREDERICK, Md., April 26, 2022 /PRNewswire-PRWeb/ -- ShiftBio, a leader in the development of innovative exosome platform technologies, announced today a strategic partnership with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services. This partnership will accelerate ShiftBio's therapeutic candidates, starting with SBI-102 (Stem cell-derived exosomes expressing a therapeutic ligand), into the clinic.

Key Points: 
  • RoosterBio will design and execute all process development studies, leveraging its industry-leading cell and media product portfolio.
  • The resulting product will be extensively characterized via state-of-the-art analytical methods to ensure identity, purity, potency, and safety of the engineered SBI-102
    exosomes.
  • "We have established a novel platform technology for exosome modifications that can address rare diseases and cancers.
  • RoosterBio accelerates human mesenchymal stem/stromal cell (hMSC) and exosome product and process development to fuel the rapid commercialization of scalable regenerative cures.

Sana Biotechnology Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates

Retrieved on: 
Wednesday, March 16, 2022
Insurance, Research, Technology, Development, Social disruption, Risk, CD8, CEO, GLP, CRISPR, Good laboratory practice, GMP, BCMA, Ion, COVID-19, Sana, Administration, National, Sutphin Boulevard station (IND Queens Boulevard Line), Board, CFA, Drug development, Immune system, Biotechnology, Good manufacturing practice, Survival, Program, Multiple myeloma, Russell Investments, Patient, Escape Room, Animal, Research and development, NASDAQ, Cell, Sale, SANA, Heart, Primate, CD22, Potency (pharmacology), CD19, Contingency (philosophy), GLOBE, Annual report, Immunity, GAAP, Fusome, Ion beam analysis, Immunosuppression, NIH, Gene editing, Company, CAR, Mouse, Terminology, Gene, Pharmaceutical industry, Mobile phone, Vaccine, Medical imaging, Online gambling, Bank, IND, Good, Beam

SEATTLE, March 16, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2021.

Key Points: 
  • Presented data highlighting ability of a single intravenous administration of SG295 to eliminate CD19+ tumor cells in mouse tumor models.
  • A discussion of non-GAAP measures, including a reconciliation of GAAP and non-GAAP measures, is presented below under Non-GAAP Financial Measures.
  • Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients.
  • The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs.